Renal, A032201 “STRIKE”

ClinicalTrials.gov ID NCT06661720

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC).

Patient Newsletter 2025 June

Patient Newsletter 2025 May

Cancer Q&A with HOA: Clinical Trials Awareness

Cancer Q&A with HOA: Women's Cancer Prevention & Treatment

Hodgkin Lymphoma, AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.

Lung, D926TC00001 “AZ Tropion-Lung12”

A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features.

Lung, 61186372NSC2012 “Copernicus”

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Practical Meditation

Yin & Sound

Pages